MCID: DYS014
MIFTS: 54

Dyspepsia

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyspepsia

MalaCards integrated aliases for Dyspepsia:

Name: Dyspepsia 12 41 14
Indigestion 12 40
Dyspepsia, Indigestion Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2321
ICD10 32 K30 R10.13
MeSH 41 D004415
NCIt 46 C26756
UMLS 69 C0013395

Summaries for Dyspepsia

MedlinePlus : 40 Nearly everyone has had indigestion at one time. It's a feeling of discomfort or a burning feeling in your upper abdomen. You may have heartburn or belch and feel bloated. You may also feel nauseated, or even throw up. You might get indigestion from eating too much or too fast, eating high-fat foods, or eating when you're stressed. Smoking, drinking too much alcohol, using some medicines, being tired, and having ongoing stress can also cause indigestion or make it worse. Sometimes the cause is a problem with the digestive tract, like an ulcer or GERD. Avoiding foods and situations that seem to cause it may help. Because indigestion can be a sign of a more serious problem, see your health care provider if it lasts for more than two weeks or if you have severe pain or other symptoms. Your health care provider may use x-rays, lab tests, and an upper endoscopy to diagnose the cause. You may need medicines to treat the symptoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Dyspepsia, also known as indigestion, is related to gastroparesis and irritable bowel syndrome. An important gene associated with Dyspepsia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Esomeprazole and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Indigestion, also known as dyspepsia, is a condition of impaired digestion. Symptoms may include upper... more...

Related Diseases for Dyspepsia

Diseases related to Dyspepsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 30.8 CCK GHRL HTR3A
2 irritable bowel syndrome 30.7 CCK HTR3A SLC6A4 TRPV1
3 bile reflux 30.1 CCK PTGS2
4 eating disorder 30.1 CCK GHRL SLC6A4
5 anxiety 30.1 CCK HTR1A HTR3A SLC6A4
6 duodenogastric reflux 29.9 CCK SST
7 gallbladder disease 29.9 CCK CCKAR SST
8 constipation 29.7 CCK HTR3A SLC6A4 SST
9 diarrhea 29.7 CCK HTR3A SST
10 migraine with or without aura 1 29.6 HTR1A HTR3A SLC6A4 TRPV1
11 disease of mental health 29.2 CCK HTR1A SLC6A4 TRPV1
12 peptic ulcer disease 29.2 CXCL8 CYP2C19 GHRL HRH2 PTGS2
13 atrophic gastritis 29.2 CXCL8 GHRL PGC
14 body mass index quantitative trait locus 11 29.1 CCK CCKAR GHRL GNB3 TRPV1
15 duodenal ulcer 29.1 CCK CXCL8 CYP2C19 HRH2 SST
16 gastritis 29.1 CXCL8 GHRL HRH2 PGC PTGS2
17 esophagitis 28.6 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
18 osteoarthritis 28.5 CXCL8 PTGS1 PTGS2
19 schizophrenia 28.3 CCK CCKAR GNB3 HRH2 HTR1A HTR3A
20 gastric ulcer 28.0 CXCL8 CYP2C19 HRH2 PTGS1 PTGS2
21 gastroesophageal reflux 27.9 CCK CXCL8 CYP2C19 GHRL HRH2 PTGS1
22 opisthorchiasis 11.0
23 duodenitis 10.4
24 pylorospasm 10.3 GHRL SST
25 social phobia 10.3 CCK HTR3A SLC6A4
26 bulimia nervosa 2 10.3 CCK GHRL SLC6A4
27 helicobacter pylori infection 10.3
28 postcholecystectomy syndrome 10.3 CCK SST
29 rumination disorder 10.2 HTR1A HTR3A
30 opioid abuse 10.2 CCK CCKAR TRPV1
31 psychosexual disorder 10.2 HTR1A SLC6A4
32 chronic laryngitis 10.2 CYP2C19 HRH2
33 phobic disorder 10.2 HTR1A SLC6A4
34 bulimia nervosa 1 10.2 CCK GHRL HTR3A SLC6A4
35 pain agnosia 10.2 CCK PTGS2 TRPV1
36 agnosia 10.2 CCK PTGS2 TRPV1
37 periodic limb movement disorder 10.2 HTR1A SLC6A4
38 pancreatic cholera 10.1 CCK HRH2 SST
39 premature ejaculation 10.1 HTR1A HTR3A SLC6A4
40 trigeminal neuralgia 10.1 SLC6A4 TRPV1
41 brunner syndrome 10.1 HTR1A HTR3A SLC6A4
42 generalized anxiety disorder 10.1 HTR1A HTR3A SLC6A4
43 aspirin resistance 10.1 PTGS1 PTGS2
44 cholelithiasis 10.1 CCK CCKAR SST
45 motion sickness 10.1 HTR1A HTR3A
46 specific developmental disorder 10.1 CCK GHRL SLC6A4 TRPV1
47 pancreas disease 10.1 CCK SST TRPV1
48 glucose metabolism disease 10.1 GHRL SST TRPV1
49 acquired metabolic disease 10.1 GHRL SST TRPV1
50 episodic pain syndrome, familial, 1 10.1

Graphical network of the top 20 diseases related to Dyspepsia:



Diseases related to Dyspepsia

Symptoms & Phenotypes for Dyspepsia

GenomeRNAi Phenotypes related to Dyspepsia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.23 HRH2 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.23 HRH2 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Dyspepsia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 HRH2 SST TRPV1 HTR1A HTR3A CCK
2 homeostasis/metabolism MP:0005376 9.9 HRH2 SST TRPV1 HTR1A HTR3A CCK
3 endocrine/exocrine gland MP:0005379 9.86 SLC6A4 HRH2 HTR3A CCK PTGS1 CCKAR
4 digestive/alimentary MP:0005381 9.8 SST HRH2 PTGS1 CCKAR PTGS2 GHRL
5 nervous system MP:0003631 9.7 HRH2 SST TRPV1 HTR1A HTR3A CCK
6 renal/urinary system MP:0005367 9.1 TRPV1 HTR3A CCK PTGS1 CCKAR PTGS2

Drugs & Therapeutics for Dyspepsia

Drugs for Dyspepsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 161796-78-7, 119141-88-7 9579578 4594
2
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
3
Famotidine Approved Phase 4,Phase 3 76824-35-6 3325
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 51-45-6, 75614-87-8 774
5
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
6
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
7
Pantoprazole Approved Phase 4,Phase 2,Phase 3 102625-70-7 4679
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
9
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 81103-11-9 84029
10
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
11
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 103577-45-3 3883
12
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
13
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
14
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 156391 1302
15
Metronidazole Approved Phase 4,Phase 3 443-48-1 4173
16
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
17
Amitriptyline Approved Phase 4,Phase 2,Phase 3 50-48-6 2160
18
Cyclobenzaprine Approved Phase 4 303-53-7 2895
19
Ranitidine Approved Phase 4,Phase 2,Phase 3 66357-59-3, 66357-35-5 3001055
20
Dopamine Approved Phase 4,Phase 3,Phase 1 51-61-6, 62-31-7 681
21
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
22
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
23
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
24
Furazolidone Approved, Investigational, Vet_approved Phase 4 67-45-8 5323714 3435
25
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
26
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
27
Magnesium Hydroxide Approved, Investigational Phase 4 1309-42-8
28
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
29
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
30
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
31
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
32
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3 93-14-1 3516
34
Tinidazole Approved, Investigational Phase 4,Phase 2,Phase 3 19387-91-8 5479
35
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
36
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
37 Racepinephrine Approved Phase 4 329-65-7
38
Loperamide Approved Phase 4,Phase 2,Phase 3 53179-11-6 3955
39
Pectin Approved, Vet_approved Phase 4 9000-69-5 441476
40
Trimebutine Approved Phase 4 39133-31-8
41
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
42 Parecoxib Approved Phase 4 198470-84-7
43
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
45
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 77-92-9 311
47
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
48 Licorice Approved, Nutraceutical Phase 4
49 Rebamipide Investigational Phase 4,Phase 3 90098-04-7
50 Mosapride Investigational Phase 4,Phase 3,Phase 1,Phase 2 112885-41-3

Interventional clinical trials:

(show top 50) (show all 330)

# Name Status NCT ID Phase Drugs
1 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
2 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
3 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4 Mirtazapine
4 The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia Unknown status NCT01608750 Phase 4 Pantoprazol;Folic Acid
5 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
6 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
7 Mast Cells in Acid-induced Intestinal Permeability Unknown status NCT02664051 Phase 4 Nalcrom;placebo
8 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
9 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
10 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
11 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
13 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
14 Buspirone Plus Omeprazole for Functional Dyspepsia Completed NCT03444831 Phase 4 Buspirone;Placebo Oral Tablet
15 Comparison of Pantoprazole and Ranitidine in Dyspepsia Completed NCT01737840 Phase 4 Pantoprazole;Ranitidine
16 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
17 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
18 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4 Omeprazole;Flupentixol-Melitracen(psychological and GI) + Omeprazole;Flupentixol-Melitracen(psychological) + Omeprazole;Flupentixol-Melitracen(without explanation) + Omeprazole
19 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
20 A Study to Demonstrate the Efficacy and Safety of Motilitone® Completed NCT01817465 Phase 4 Motilitone ®;Pantoline®;Motilitone® and Pantoline®
21 The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study Completed NCT02460601 Phase 4 Qizhiweitong granule
22 A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain Completed NCT02197143 Phase 4 esomeprazole;Ranitidine;hydrotalcid
23 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
24 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
25 Proton Pump Inhibitor Treatment Stop Completed NCT00120315 Phase 4 esomeprazole
26 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
27 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
28 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
29 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole Completed NCT01281501 Phase 4 Normal saline;Pantoprazole;Oral antacid;Hyoscine butylbromide
30 Amtolmetin Gaucil in Knee Osteoarthritis Completed NCT02865161 Phase 4 NISELAT
31 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
32 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
33 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
34 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
35 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
36 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone
37 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
38 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
39 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
40 Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients Completed NCT00650455 Phase 4 valdecoxib;naproxen;placebo
41 Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
42 Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain Completed NCT00649610 Phase 4 valdecoxib;diclofenac
43 Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients Recruiting NCT03119766 Phase 4 Kolofort;Placebo
44 BRAVO Study for Functional Dyspepsia Recruiting NCT01349413 Phase 4 Esomeprazole 20mg
45 Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms Recruiting NCT02775591 Phase 4 DA-9701;DA-9701 placebo
46 Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy Recruiting NCT02105090 Phase 4 Anesthetics, Local;Sodium Chloride 0.9%
47 PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms Recruiting NCT02476097 Phase 4 Esomeprazole: Nexium® 20mg, Astra Zeneca;Placebo
48 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Recruiting NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
49 Heweizhixie capsuleTherapy on Patients With Diarrhea Recruiting NCT02607176 Phase 4 Heweizhixie capsule
50 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole

Search NIH Clinical Center for Dyspepsia

Cochrane evidence based reviews: dyspepsia

Genetic Tests for Dyspepsia

Anatomical Context for Dyspepsia

MalaCards organs/tissues related to Dyspepsia:

38
Testes, Kidney, Brain, Small Intestine, Liver, Heart, Tongue

Publications for Dyspepsia

Articles related to Dyspepsia:

(show top 50) (show all 793)
# Title Authors Year
1
Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. ( 29396034 )
2018
2
Mechanism of Action of STWA 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target. ( 29421789 )
2018
3
Exploring current status of Helicobacter pylori infection in different age groups of patients with dyspepsia. ( 29368191 )
2018
4
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. ( 29411724 )
2018
5
New Medical Approach to Functional Dyspepsia, from Core Symposium 3, Japan Gastroenterological Association 2015-2017. ( 29393229 )
2018
6
Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. ( 29392796 )
2018
7
Complementary and alternative treatment in functional dyspepsia. ( 29435308 )
2018
8
Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia. ( 29449092 )
2018
9
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
10
Abnormal Gastrointestinal Imaging in a Patient with Dyspepsia. ( 29409878 )
2018
11
New insights into functional dyspepsia: further evidence for postprandial distress syndrome as a distinct disease. ( 29396033 )
2018
12
Management of dyspepsia-The role of the emergency department observation unit to optimize patient outcomes. ( 29444751 )
2018
13
Helicobacter pylori among patients with uninvestigated dyspepsia: issues to be remembered. ( 29384763 )
2018
14
The association between adult-type hypolactasia and symptoms of functional dyspepsia. ( 29384557 )
2018
15
Effect of Zhizhu Kuanzhong capsule on functional dyspepsia: Protocol for a systematic review and meta-analysis of randomized controlled trials. ( 29419664 )
2018
16
Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. ( 29373960 )
2018
17
Weikangning therapy in functional dyspepsia and the protective role of Nrf2. ( 28928800 )
2017
18
A magnetic resonance imaging study of gastric motor function in patients with dyspepsia associated with Ehlers-Danlos Syndrome-Hypermobility Type: A feasibility study. ( 28568908 )
2017
19
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017
20
Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome - a population based study. ( 28521729 )
2017
21
Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia? ( 28818267 )
2017
22
Modified Helicobacter test using a new test meal and a (13)C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors. ( 28932087 )
2017
23
Exhaled nitric oxide as a potential marker for detecting non-ulcer dyspepsia and peptic ulcer disease. ( 28947681 )
2017
24
"First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. ( 28932929 )
2017
25
Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical study. ( 28852318 )
2017
26
Food and functional dyspepsia: a systematic review. ( 28913843 )
2017
27
Celiac disease prevalence is not increased in patients with functional dyspepsia. ( 28079237 )
2017
28
Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol. ( 28951846 )
2017
29
Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. ( 27973922 )
2017
30
Acupuncture and related therapies used as add-on or alternative to prokinetics for functional dyspepsia: overview of systematic reviews and network meta-analysis. ( 28871092 )
2017
31
Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. ( 27958284 )
2017
32
How should we manage patients with functional dyspepsia in clinical practice? ( 28884565 )
2017
33
Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. ( 28854971 )
2017
34
The Role of Duodenal Inflammation in Functional Dyspepsia. ( 27811629 )
2017
35
Plasma ghrelin level and plasma ghrelin/obestatin ratio are related to intestinal metaplasia in elderly patients with functional dyspepsia. ( 28419119 )
2017
36
Definition, Pathogenesis and Management of that cursed Dyspepsia. ( 28899670 )
2017
37
Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). ( 28925989 )
2017
38
Functional dyspepsia. ( 29375182 )
2017
39
Superior Mesenteric Artery Syndrome May Be Overlooked in Women with Functional Dyspepsia. ( 28883239 )
2017
40
An unusual cause of dyspepsia due to a retained epicardial pacing wire. ( 29364103 )
2017
41
Effectiveness of Quercus brantii hydroalcoholic extract on dyspepsia: A randomized, double blind clinical trial. ( 28852653 )
2017
42
Diffuse nodular duodenitis in a woman presenting with dyspepsia and weight loss. ( 29364111 )
2017
43
Certain Dietary Habits Contribute to the Functional Dyspepsia in South China Rural Area. ( 28809820 )
2017
44
Impaired vagal activity to meal in patients with functional dyspepsia and delayed gastric emptying. ( 28874084 )
2017
45
Gender Difference of Gastric Emptying in Healthy Volunteers and Patients with Functional Dyspepsia. ( 28052285 )
2017
46
The efficiency of Levofloxacin Containing Sequential Therapy with or without Bismuth, in Helicobacter Pylori Eradication, in Non-ulcer Dyspepsia. ( 29364096 )
2017
47
Editorial: Moving Away From Focussing on Gastric Pathophysiology in Functional Dyspepsia: New Insights and Therapeutic Implications. ( 28050031 )
2017
48
Functional dyspepsia and gastroparesis. ( 28832359 )
2017
49
Gastric siderosis as a cause of dyspepsia. ( 27511759 )
2016
50
Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. ( 27022230 )
2016

Variations for Dyspepsia

Expression for Dyspepsia

Search GEO for disease gene expression data for Dyspepsia.

Pathways for Dyspepsia

Pathways related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 CCK CCKAR CXCL8 GHRL GNB3 HRH2
2 12.29 GNB3 HTR1A PTGS1 PTGS2
3
Show member pathways
11.74 GNB3 HTR1A HTR3A
4
Show member pathways
11.67 CYP2C19 PTGS1 PTGS2
5 11.65 CXCL8 GNB3 HTR1A HTR3A SLC6A4 SST
6 11.25 CYP2C19 GNB3 PTGS1
7 11.22 CYP2C19 GNB3 HTR1A HTR3A PTGS1 PTGS2
8
Show member pathways
10.96 PTGS1 PTGS2
9 10.94 HTR1A HTR3A SLC6A4
10 10.89 PTGS1 PTGS2
11 10.86 PTGS1 PTGS2
12 10.61 CXCL8 PTGS1 PTGS2
13 10.58 PTGS1 PTGS2

GO Terms for Dyspepsia

Cellular components related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.46 CCK HTR3A SST TRPV1
2 neuron projection GO:0043005 9.26 GNB3 PTGS2 SLC6A4 TRPV1
3 organelle membrane GO:0031090 8.8 CYP2C19 PTGS1 PTGS2

Biological processes related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CXCL8 PTGS1 PTGS2 TRPV1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 CCKAR GHRL TRPV1
3 response to nutrient GO:0007584 9.63 CCKAR SLC6A4 SST
4 excitatory postsynaptic potential GO:0060079 9.61 GHRL HTR3A TRPV1
5 memory GO:0007613 9.58 HRH2 PTGS2 SLC6A4
6 decidualization GO:0046697 9.57 GHRL PTGS2
7 prostaglandin metabolic process GO:0006693 9.54 PTGS1 PTGS2
8 regulation of blood pressure GO:0008217 9.54 GNB3 PTGS1 PTGS2
9 vasoconstriction GO:0042310 9.52 HTR1A SLC6A4
10 prostaglandin biosynthetic process GO:0001516 9.51 PTGS1 PTGS2
11 digestion GO:0007586 9.5 CCKAR PGC SST
12 cellular response to ATP GO:0071318 9.49 PTGS2 TRPV1
13 cyclooxygenase pathway GO:0019371 9.48 PTGS1 PTGS2
14 response to organonitrogen compound GO:0010243 9.33 PTGS2 SST TRPV1
15 regulation of hormone secretion GO:0046883 9.26 CCKAR HTR1A
16 G-protein coupled receptor signaling pathway GO:0007186 9.23 CCK CCKAR CXCL8 GHRL GNB3 HRH2
17 negative regulation of synaptic transmission, dopaminergic GO:0032227 8.96 PTGS2 SLC6A4
18 signal transduction GO:0007165 10.12 CCK CCKAR CXCL8 GNB3 HRH2 HTR1A

Molecular functions related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.67 CCKAR GNB3 HRH2 HTR1A
2 heme binding GO:0020037 9.43 CYP2C19 PTGS1 PTGS2
3 hormone activity GO:0005179 9.33 CCK GHRL SST
4 peroxidase activity GO:0004601 9.32 PTGS1 PTGS2
5 serotonin binding GO:0051378 8.96 HTR1A HTR3A
6 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Dyspepsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....